Trevi Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89532M1018

SecurityTRVI / Trevi Therapeutics, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership103,967 shares
Latest Disclosed Value $ 1,240,326
Squarepoint Ops LLC ownership in TRVI / Trevi Therapeutics, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 103,967 shares of Trevi Therapeutics, Inc. (US:TRVI) valued at $1,240,326 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of Trevi Therapeutics, Inc.. The current value of the position is $1,398,356 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TREVI THERAPEUTICS COM 89532M101 103,967 103,967 1,240 0.0015
2025-11-14 2025-09-30 13F TREVI THERAPEUTICS COM 89532M101 0 -19,149 -100.00 0 -100.00
2025-08-27 2025-06-30 13F/A-1 TREVI THERAPEUTICS COM 89532M101 19,149 -55,403 -74.31 105 -77.78 0.0001
2025-08-14 2025-06-30 13F TREVI THERAPEUTICS COM 89532M101 19,149 -55,403 105 0.0001
2025-08-27 2025-03-31 13F/A-1 TREVI THERAPEUTICS COM 89532M101 74,552 60,493 430.28 469 721.05 0.0006
2025-05-15 2025-03-31 13F TREVI THERAPEUTICS COM 89532M101 74,552 60,493 469 0.0006
2025-02-14 2024-12-31 13F TREVI THERAPEUTICS COM 89532M101 14,059 14,059 58 0.0001
2024-08-14 2024-06-30 13F TREVI THERAPEUTICS COM 89532M101 0 -15,027 -100.00 0 -100.00
2024-05-15 2024-03-31 13F TREVI THERAPEUTICS COM 89532M101 15,027 -84,464 -84.90 52 -61.65 0.0001
2024-02-14 2023-12-31 13F TREVI THERAPEUTICS COM 89532M101 99,491 99,491 133 0.0003
2023-08-14 2023-06-30 13F TREVI THERAPEUTICS COM 89532M101 0 -11,474 -100.00 0 -100.00
2023-05-15 2023-03-31 13F TREVI THERAPEUTICS COM 89532M101 11,474 11,474 21 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.